Syed, Farhatullah and McCrae, Malcolm A.. (2009) Interactions in vivo between the Vif protein of HIV-1 and the precursor (Pr55GAG) of the virion nucleocapsid proteins. Archives of Virology, Vol.15 (No.11). pp. 1797-1805. ISSN 0304-8608

Preview

PDF WRAP_McCrae_Vifarchivesrevised.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (487Kb)

Abstract

The abnormality of viral core structure seen in vif-defective HIV-1 grown in PBMCs has suggested a role for Vif in viral morphogenesis. Using an in vivo mammalian two-hybrid assay, the interaction between Vif and the precursor (Pr55GAG) of the virion nucleocapsid proteins has been analysed. This revealed the amino-terminal (aa 1–22) and central (aa 70–100) regions of Vif to be essential for its interaction with Pr55GAG, but deletion of the carboxy-terminal (aa 158–192) region of the protein had only a minor effect on its interaction. Initial deletion studies carried out on Pr55GAG showed that a 35-amino-acid region of the protein bridging the MA(p17)–CA(p24) junction was essential for its ability to interact with Vif. Site-directed mutagenesis of a conserved tryptophan (Trp21) near the amino terminus of Vif showed it to be important for the interaction with Pr55GAG. By contrast, mutagenesis of the highly conserved YLAL residues forming part of the BC-box motif, shown to be important in Vif promoting degradation of APOBEC3G/3F, had little or no effect on the Vif–Pr55GAG interaction.

Item Type:	Journal Article
Subjects:	Q Science > QR Microbiology > QR355 Virology
Divisions:	Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH):	HIV (Viruses) -- Research, Viruses -- Morphogenesis, Viral proteins -- Research, Viral genetics
Journal or Publication Title:	Archives of Virology
Publisher:	Springer Wien
ISSN:	0304-8608
Date:	November 2009
Volume:	Vol.15
Number:	No.11
Page Range:	pp. 1797-1805
Identification Number:	10.1007/s00705-009-0520-8
Status:	Peer Reviewed
Access rights to Published version:	Open Access
References:	1. Adekale MA, Cane PA, McCrae MA (2005) Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease. J Med Virol 75:195–201 2. Arya SK, Guo C, Josephs SF, Wong-Staal F (1985) Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229:69–73 3. Baraz L, Hutoran M, Blumenzweig I, Katzenellenbogen M, Friedler A, Gilon C, Steinitz M, Kotler M (2002) Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. J Gen Virol 83:2225–2230 4. Borman AM, Quillent C, Charneau P, Dauguet C, Clavel F (1995) Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol 69:2058–2067 5. Bouyac M, Courcoul M, Bertoia G, Baudat Y, Gabuzda D, Blanc D, Chazal N, Boulanger P, Sire J, Vigne R, Spire B (1997) Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol 71:9358–9365 6. Bouyac M, Rey F, Nascimbeni M, Courcoul M, Sire J, Blanc D, Clavel F, Vigne R, Spire B (1997) Phenotypically Vif-human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol 71:2473–2477 7. Boyce M, Willingmann P, McCrae M (1999) Identification of a functionally important amino acid residue near to the amino-terminus of the human immunodeficiency virus type 1 Vif protein. Virus Genes 19:15–22 8. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L (2004) The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279:33177–33184 9. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13:2009–2013 10. Desrosiers RC (1992) HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses 8:411–421 11. Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe DE, Tritch R, Hutchison CA 3rd, Loeb DD, Swanstrom R (1989) Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses 5:577–591 12. Fan L, Peden K (1992) Cell-free transmission of Vif mutants of HIV-1. Virology 190:19–29 13. Fouchier RA, Simon JH, Jaffe AB, Malim MH (1996) Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol 70:8263–8269 14. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J (1992) Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 66:6489–6495 15. Gabuzda DH, Li H, Lawrence K, Vasir BS, Crawford K, Langhoff E (1994) Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr 7:908–915 16. Gluzman Y (1981) SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23:175–182 17. Harmache A, Russo P, Guiguen F, Vitu C, Vignoni M, Bouyac M, Hieblot C, Pepin M, Vigne R, Suzan M (1996) Requirement of caprine arthritis encephalitis virus vif gene for in vivo replication. Virology 224:246–255 18. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113:803–809 19. Hoglund S, Ohagen A, Lawrence K, Gabuzda D (1994) Role of vif during packing of the core of HIV-1. Virology 201:349–355 20. Imai Y, Nakamura M (1988) The importance of threonine-301 from cytochromes P-450 (laurate (omega-1)-hydroxylase and testosterone 16 alpha-hydroxylase) in substrate binding as demonstrated by site-directed mutagenesis. FEBS Lett 234:313–315 21. Lee TH, Coligan JE, Allan JS, McLane MF, Groopman JE, Essex M (1986) A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science 231:1546–1549 22. Liu B, Yu X, Luo K, Yu Y, Yu XF (2004) Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 78:2072–2081 23. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF (2005) Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 79:9579–9587 24. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 78:11841–11852 25. Madani N, Kabat D (1998) An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 72:10251–10255 26. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99–103 27. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9:1398–1403 28. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 18:2861–2866 29. Oberste MS, Gonda MA (1992) Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes 6:95–102 30. Ochman H, Gerber AS, Hartl DL (1988) Genetic applications of an inverse polymerase chain reaction. Genetics 120:621–623 31. Sadowski I, Bell B, Broad P, Hollis M (1992) GAL4 fusion vectors for expression in yeast or mammalian cells. Gene 118:137–141 32. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646–650 33. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:1404–1407 34. Simon JH, Gaddis NC, Fouchier RA, Malim MH (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 4:1397–1400 35. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12:591–601 36. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 80:3112–3115 37. Vasavada HA, Ganguly S, Germino FJ, Wang ZX, Weissman SM (1991) A contingent replication assay for the detection of protein–protein interactions in animal cells. Proc Natl Acad Sci USA 88:10686–10690 38. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056–1060 39. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 18:2867–2872 40. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94–98 41. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78:6073–6076.
URI:	http://wrap.warwick.ac.uk/id/eprint/2249

Request changes to a record

Actions (login required)

View Item